175 related articles for article (PubMed ID: 35047498)
21. Immunological classification of hepatitis B virus-positive hepatocellular carcinoma by transcriptome analysis.
Li SW; Han LF; He Y; Wang XS
World J Hepatol; 2022 Dec; 14(12):1997-2011. PubMed ID: 36618328
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Xiao W; Zhang G; Chen B; Chen X; Wen L; Lai J; Li X; Li M; Liu H; Liu J; Han-Zhang H; Lizaso A; Liao N
Front Oncol; 2021; 11():618767. PubMed ID: 33968723
[TBL] [Abstract][Full Text] [Related]
24. Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.
Eng J; Thibault G; Luoh SW; Gray JW; Chang YH; Chin K
Methods Mol Biol; 2020; 2055():521-562. PubMed ID: 31502168
[TBL] [Abstract][Full Text] [Related]
25. Classification of Estrogen Receptor-Positive Breast Cancer Based on Immunogenomic Profiling and Validation at Single-Cell Resolution.
Ma X; Chen H; Yang M; Ke Z; Wang M; Huang T; Li L
Front Cell Dev Biol; 2021; 9():722841. PubMed ID: 34621742
[No Abstract] [Full Text] [Related]
26. Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
Hu R; Tao T; Yu L; Ding Q; Zhu G; Peng G; Zheng S; Yang L; Wu S
Front Cell Dev Biol; 2021; 9():809588. PubMed ID: 35223867
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling identified TP53
Cheng J; Ding X; Xu S; Zhu B; Jia Q
Oncol Lett; 2020 Apr; 19(4):2817-2824. PubMed ID: 32218835
[TBL] [Abstract][Full Text] [Related]
28. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.
Routh ED; Van Swearingen AED; Sambade MJ; Vensko S; McClure MB; Woodcock MG; Chai S; Cuaboy LA; Wheless A; Garrett A; Carey LA; Hoyle AP; Parker JS; Vincent BG; Anders CK
Front Oncol; 2022; 12():818693. PubMed ID: 35992833
[TBL] [Abstract][Full Text] [Related]
30. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
31. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
32. Immunogenic cell death-related classifications in breast cancer identify precise immunotherapy biomarkers and enable prognostic stratification.
Wang X; Huang H; Liu X; Li J; Wang L; Li L; Li Y; Han T
Front Genet; 2022; 13():1052720. PubMed ID: 36437951
[No Abstract] [Full Text] [Related]
33. A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy.
Jin K; He M; Chen B; Zhou X; Zhang C; Zhang Z; Hu D; Jiang Z; Wei Q; Qiu S; Yang L
Transl Androl Urol; 2022 Jul; 11(7):943-958. PubMed ID: 35958899
[TBL] [Abstract][Full Text] [Related]
34. TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer.
Zhang Z; Hao R; Guo Q; Zhang S; Wang X
Front Cell Dev Biol; 2021; 9():759154. PubMed ID: 34917611
[No Abstract] [Full Text] [Related]
35. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
Criscitiello C; Marra A; Morganti S; Zagami P; Gandini S; Esposito A; Curigliano G
Eur J Cancer; 2021 Nov; 157():40-49. PubMed ID: 34474219
[TBL] [Abstract][Full Text] [Related]
36. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic-associated molecular subtypes and genomic mutations.
Li L; Wu N; Zhuang G; Geng L; Zeng Y; Wang X; Wang S; Ruan X; Zheng X; Liu J; Gao M
Front Pharmacol; 2023; 14():1224828. PubMed ID: 37719859
[No Abstract] [Full Text] [Related]
38. A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer.
Wang C; Xu K; Deng F; Liu Y; Huang J; Wang R; Guan X
Transl Cancer Res; 2021 May; 10(5):2229-2246. PubMed ID: 35116541
[TBL] [Abstract][Full Text] [Related]
39. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
40. Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.
Xu M; Lu JH; Zhong YZ; Jiang J; Shen YZ; Su JY; Lin SY
Front Oncol; 2022; 12():870914. PubMed ID: 35444934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
